SCHEMBL7127097

SCHEMBL7127097

FC(F)(F)c1ccccc1OCCN1CCN(C2=COC(C3=CC=CCC3)=CO2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 9/20 0.43
LTA4H P09960 1/20 0.40
PTGS2 P35354 1/20 0.40
HTR1A P08908 3/20 0.39
HTR7 P34969 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
HSD17B10 Q99714 1/20 0.38
HTR2A P28223 2/20 0.35
HTR2C P28335 1/20 0.35
ALDH1A1 P00352 1/20 0.34
FAAH O00519 1/20 0.34
BCHE P06276 1/20 0.34
ACHE P22303 1/20 0.34
HTR1D P28221 1/20 0.34
HTR1B P28222 1/20 0.34
GNRHR P30968 1/20 0.34
DRD3 P35462 2/20 0.33
DRD1 P21728 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7130709 0.85 L3MBTL1 (0.41) DRD2HTR1AALDH1A1DRD3DRD1
SCHEMBL7125207 0.84 KDM4E (0.47) DRD2HTR1ACYP1A2CYP2D6CYP2C19
SCHEMBL4877091 0.82 HTR1A (0.35) DRD2HTR1AHTR7HTR2AHTR2C
SCHEMBL7116018 0.82 HTR2A (0.34) HTR2AHTR2C
SCHEMBL4877185 0.82 SLC6A2 (0.34) DRD2HTR1AHTR2AHTR1DHTR1B
SCHEMBL4871961 0.82 SLC6A2 (0.34) DRD2HTR1AHTR2AALDH1A1DRD3
SCHEMBL7128466 0.82 L3MBTL1 (0.47) DRD2HTR1ACYP1A2CYP2D6CYP2C19
SCHEMBL7127857 0.81 HTR2A (0.32) DRD2HTR1AHTR7HTR2AHTR2C
SCHEMBL7128136 0.80 ALDH1A1 (0.42) DRD2HTR1AHTR7HTR2AALDH1A1
SCHEMBL7127138 0.80 HTR1A (0.44) DRD2HTR1AHTR7HTR2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030050306-A1 Novel heteroaryl derivatives, their preparation and use H. LUNDBECK A/S (DK) 2003-03-13 US claimed
EP-1246820-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2002-10-09 EP claimed
WO-2001049683-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2001-07-12 WO claimed
US-20030050306-A1 Novel heteroaryl derivatives, their preparation and use H. LUNDBECK A/S (DK) 2003-03-13 US disclosed
EP-1246820-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2002-10-09 EP disclosed
WO-2001049683-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2001-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050306-A1 Novel heteroaryl derivatives, their preparation and use CRBN, CDR2, DRD3 DRD2 7/4885LTA4H 4863/4885PTGS2 4699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.